Abstract:
The present invention provides a patch deployment device, the device comprising a pusher wire having a proximal end and a distal end; a plurality of deployment wires, wherein each deployment wire: has a first end and a second end, and the first end and the second end are connected to the distal end of the pusher wire; and is configured to be in an unexpanded state when positioned and constrained within a catheter, and configured to self-expand into an expanded state when positioned beyond a distal end of the catheter and not constrained, wherein in the expanded state at least a portion of the wire is positioned substantially within a plane that is substantially perpendicular to the longitudinal axis of the pusher wire and has an asymmetric form when viewed along a direction parallel to the longitudinal axis of the pusher wire.
Abstract:
Non-invasive method for the diagnosis or screening of colorectal cancer and/or pre-cancerous stage thereof. The present invention refers to an in vitro method for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof.
Abstract:
Patch (1) for sealing an amniotic membrane, wherein the patch (1) comprises a support (11) and an adhesive (12) that is activated in presence of amniotic liquid or a wet environment. Device for placing said patch (1) comprising a cannula (2) for inserting said patch (1) in a rolled-up position, said cannula (2) being provided with a handle (3); and a dipstick (4) provided with a pusher (5), said dipstick (4) being inserted inside the cannula (2) in the use position. The patch adheres efficiently on the amniotic membrane, adapts to the elastic properties of this membrane, and by attaching only to the amnion it does not interfere with the natural sliding movements of one membrane against each other, together with the device to ensure that the patch is placed in the proper position without damaging the membrane.
Abstract:
The invention relates to methods for diagnosing type 2 diabetes as well as antidiabetic agents for use in the treatment of type 2 diabetes. The invention relates as well to kits and nucleic acids for carrying out the diagnostic methods.
Abstract:
Las sales de tungstatode metales farmacéuticamente aceptables, o sus solvatos,son útiles para reducir la reactividad de las plaquetas en un mamífero, incluido un humano, y se pueden utilizar para tratar a sujetos que padecen una condición o enfermedad vascular asociada a plaquetas.
Abstract:
The present invention refers to a CD19-specific chimeric antigen receptor (CAR) T-cell therapy and to its use for treating CD19+ malignancies.
Abstract:
A method and a system for determining the amount of oxygen required by a user with respiratory problems are disclosed. First data about several users with respiratory problems is stored in a database. The method a) collects second data from a monitored user while (s)he is performing a test at a first location; b) computes a user's behavioral model executing a first algorithm on the first and second data; c) collects, every period of time t1, third data of the user while (s)he is performing an activity at a second location; d) adjusts, every period of time t2, the computed user's behavioral model using the first algorithm, providing a customized user's behavioral model as a result; and e) computes an estimator of the quantity of oxygen to be delivered to the user by executing a second algorithm on the customized user's behavioral model.
Abstract:
A method for predicting the therapeutic response and/or prognosis in a subject suffering Chagas disease and uses thereof are disclosed. The method comprises the analysis of an isolated biological sample, wherein it is detected at least one protein expression product comprising human and/or T. cruzi parasite proteins, said human proteins including at least one of: the group of mannose-binding lectin-associated serine proteins 2, MASP2, the group of angiopoietin-related proteins, the group of collagen alpha-2 chain, VI, and the group of myosin regulatory light chain 12A, and said T. cruzi parasite protein including pyruvate phosphate dikinase, such that the detected protein expression product can serve as potential biomarker in the context of the therapeutic response and prognosis of the disease during chronic infection.
Abstract:
La presente invención se refiere a una composición que comprende ácido úrico para su uso en el tratamiento de infarto cerebral en un paciente tratado también mediante trombectomía mecánica.
Abstract:
The invention provides methods for predicting response to anti-TNFα biological agent treatment in a rheumatoid arthritis patient and methods for selecting a treatment for a rheumatoid arthritis patient, the methods comprising determining the level of expression of PIK3CD as a biomarker, and optionally also determining the level of expression of CX3CL1 as a second biomarker. The invention additionally provides kits for carrying out the methods described.